Table 2 Univariable regression analysis between VAT measurement methods to metabolic risk factors.

From: Association between visceral adipose tissue volume, measured using computed tomography, and cardio-metabolic risk factors

 

VAT volume (cm3)

VAT area (L2 level, cm2)

VAT area (Umbilicus level, cm2)

Triglyceride

Correlation coefficient

0.309

0.379

0.337

Significance Level P

0.007

0.008

0.003

HDL-cholesterol

Correlation coefficient

 − 0.335

 − 0.290

 − 0.224

Significance Level P

0.003

0.012

0.053

Fasting blood glucose

Correlation coefficient

0.292

0.021

0.093

Significance Level P

0.011

0.856

0.427

Systolic blood pressure

Correlation coefficient

0.035

 − 0.000

0.015

Significance Level P

0.771

0.998

0.900

Diastolic blood pressure

Correlation coefficient

0.082

 − 0.174

 − 0.073

Significance Level P

0.494

0.146

0.545

HOMA-IR

Correlation coefficient

0.469

0.019

 − 0.022

Significance Level P

 < 0.001

0.869

0.849

QUICKI

Correlation coefficient

 − 0.50

 − 0.036

0.017

Significance Level P

 < 0.001

0.762

0.886

Matsuda index

Correlation coefficient

 − 0.415

0.000

0.052

Significance Level P

0.003

0.999

0.724

HOMA-β

Correlation coefficient

0.212

 − 0.046

 − 0.158

Significance Level P

0.067

0.696

0.176

Insuliogenic index

Correlation coefficient

0.015

0.034

 − 0.010

Significance Level P

0.898

0.774

0.933

Hepatic steatosis index

Correlation coefficient

0.438

0.166

0.155

Significance Level P

0.0001

0.167

0.197

NAFLD liver fat score

Correlation coefficient

0.496

0.078

0.110

Significance Level P

 < 0.0001

0.519

0.360

Framinghan steatosis index

Correlation coefficient

0.531

0.440

0.413

Significance Level P

 < 0.0001

0.002

0.005

  1. VAT, visceral adipose fat tissue; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance, HOMA-β, homeostatic model assessment of β-cell function; QUICKI, quantitative insulin sensitivity check index; NAFLD, nonalcoholic fatty liver disease.